Back to Search
Start Over
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.
- Source :
-
Journal of the American College of Cardiology [J Am Coll Cardiol] 2013 Oct 01; Vol. 62 (14), pp. 1267-1276. Date of Electronic Publication: 2013 Jul 03. - Publication Year :
- 2013
-
Abstract
- Objectives: The aim of this study was to develop ribonucleic acid (RNA) profiles that could serve as novel biomarkers for the response to aspirin.<br />Background: Aspirin reduces death and myocardial infarction (MI), suggesting that aspirin interacts with biological pathways that may underlie these events.<br />Methods: Aspirin was administered, followed by whole-blood RNA microarray profiling, in a discovery cohort of healthy volunteers (HV1) (n = 50) and 2 validation cohorts of healthy volunteers (HV2) (n = 53) and outpatient cardiology patients (OPC) (n = 25). Platelet function was assessed using the platelet function score (PFS) in HV1 and HV2 and the VerifyNow Aspirin Test (Accumetrics, Inc., San Diego, California) in OPC. Bayesian sparse factor analysis identified sets of coexpressed transcripts, which were examined for associations with PFS in HV1 and validated in HV2 and OPC. Proteomic analysis confirmed the association of validated transcripts in platelet proteins. Validated gene sets were tested for association with death or MI in 2 patient cohorts (n = 587 total) from RNA samples collected at cardiac catheterization.<br />Results: A set of 60 coexpressed genes named the "aspirin response signature" (ARS) was associated with PFS in HV1 (r = -0.31, p = 0.03), HV2 (r = -0.34, Bonferroni p = 0.03), and OPC (p = 0.046). Corresponding proteins for the 17 ARS genes were identified in the platelet proteome, of which 6 were associated with PFS. The ARS was associated with death or MI in both patient cohorts (odds ratio: 1.2 [p = 0.01]; hazard ratio: 1.5 [p = 0.001]), independent of cardiovascular risk factors. Compared with traditional risk factors, reclassification (net reclassification index = 31% to 37%, p ≤ 0.0002) was improved by including the ARS or 1 of its genes, ITGA2B.<br />Conclusions: RNA profiles of platelet-specific genes are novel biomarkers for identifying patients who do not respond adequately to aspirin and who are at risk for death or MI.<br /> (Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Bayes Theorem
Blood Platelets drug effects
Cardiovascular Diseases blood
Cardiovascular Diseases drug therapy
Genes drug effects
Humans
Microarray Analysis
Platelet Aggregation Inhibitors therapeutic use
Platelet Function Tests
Real-Time Polymerase Chain Reaction
Risk Factors
Aspirin therapeutic use
Blood Platelets physiology
Cardiovascular Diseases genetics
Genes genetics
Proteomics methods
RNA analysis
Subjects
Details
- Language :
- English
- ISSN :
- 1558-3597
- Volume :
- 62
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Journal of the American College of Cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 23831034
- Full Text :
- https://doi.org/10.1016/j.jacc.2013.05.073